Cell Therapy Manufacturing – Opportunities and Challenges

In this podcast, we interviewed Dr. Robert Preti about the past, present, and future of global cell therapy manufacturing. We also discussed major industry milestones, manufacturing challenges, and opportunities for the further improvements.
View show notes at cellculturedish.com/cell-therapy-manufacturing-opportunities-challenges/
Robert A. Preti, PhDChief Executive Officer and President, Hitachi Chemical Advanced Therapeutics Solutions, LLCGeneral Manager, Regenerative Medicine Business Sector, Hitachi Chemical Co. Ltd.
Dr. Robert “Bob” Preti is the co-founder and the visionary behind the successful growth and development strategy of PCT (on October 2, 2017 renamed Hitachi Chemical Advanced Therapeutics Solutions, LLC or “HCATS”) over much of the last two decades. Upon PCT’s acquisition by Hitachi Chemical Co., Ltd. in May 2017, Bob’s role expanded to General Manager, Regenerative Medicine Business Sector of Hitachi Chemical, responsible for development, management and oversight of the global business operations of Hitachi Chemical’s regenerative medicine business unit. Bob built HCATS to meet a recognized need for high quality manufacturing and development services in an emerging industry. Bob is currently Chairman for the Alliance for Regenerative Medicine, where, among other activities, he previously served as Vice Chairman and in other roles. Bob holds a BS degree in biology from Fordham University, and a MS degree and Doctorate, both in biology, from New York University.